The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 weeks in patients with primary immunoglobulin A nephropathy.

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, ...

NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of ...